铜绿假单胞菌生物膜、囊性纤维化和噬菌体：一线希望？
Pseudomonas biofilms, cystic fibrosis, and phage: a silver lining?
机构信息
Nestlé Research Center, BioAnalytical Department, Food and Health Microbiology Group, Lausanne, Switzerland.
出版信息
mBio. 2012 Apr 3;3(2). doi: 10.1128/mBio.00061-12. Print 2012.
Abstract
In contrast to usual laboratory conditions, most bacteria in the human body grow in biofilms. Encased in a structured matrix, many pathogens display heightened resistance to antibiotics. Pseudomonas aeruginosa lung infections in cystic fibrosis patients represent a prime example of the clinical challenges that antibiotic resistance in biofilms can represent. In the March 6, 2012 issue of mBio, Colin Hill and his colleagues report on experiments that add to the evidence that Pseudomonas phages are a potential treatment option for these infections.
摘要
与通常的实验室条件相比，人体中的大多数细菌都生长在生物膜中。许多病原体被包裹在结构化的基质中，表现出对抗生素更高的抵抗力。囊性纤维化患者肺部的铜绿假单胞菌感染就是生物膜中抗生素耐药性带来的临床挑战的一个典型例子。在 2012 年 3 月 6 日的 mBio 杂志上，Colin Hill 及其同事报告了一些实验，这些实验进一步证明了假单胞菌噬菌体是治疗这些感染的一种潜在治疗选择。
相似文献
1
Pseudomonas biofilms, cystic fibrosis, and phage: a silver lining?铜绿假单胞菌生物膜、囊性纤维化和噬菌体：一线希望？
mBio. 2012 Apr 3;3(2). doi: 10.1128/mBio.00061-12. Print 2012.
2
Bacteriophages φMR299-2 and φNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells.噬菌体 φMR299-2 和 φNH-4 可以消除肺部的铜绿假单胞菌和囊性纤维化肺气道细胞中的铜绿假单胞菌。
mBio. 2012 Mar 6;3(2):e00029-12. doi: 10.1128/mBio.00029-12. Print 2012.
3
Bacteriophage PEV20 and Ciprofloxacin Combination Treatment Enhances Removal of Pseudomonas aeruginosa Biofilm Isolated from Cystic Fibrosis and Wound Patients.噬菌体 PEV20 与环丙沙星联合治疗增强了从囊性纤维化和创伤患者中分离的铜绿假单胞菌生物膜的清除。
AAPS J. 2019 Apr 4;21(3):49. doi: 10.1208/s12248-019-0315-0.
4
Bacteriophages of Pseudomonas aeruginosa: long-term prospects for use in phage therapy.铜绿假单胞菌噬菌体：噬菌体疗法的长期前景。
Adv Virus Res. 2014;88:227-78. doi: 10.1016/B978-0-12-800098-4.00005-2.
5
Assessing phage therapy against Pseudomonas aeruginosa using a Galleria mellonella infection model.利用家蚕感染模型评估噬菌体疗法对铜绿假单胞菌的作用。
Int J Antimicrob Agents. 2015 Aug;46(2):196-200. doi: 10.1016/j.ijantimicag.2015.04.005. Epub 2015 May 27.
6
Pseudomonas aeruginosa bacteriophage PA1Ø requires type IV pili for infection and shows broad bactericidal and biofilm removal activities.铜绿假单胞菌噬菌体 PA1Ø 需要 IV 型菌毛才能感染，并表现出广泛的杀菌和生物膜清除活性。
Appl Environ Microbiol. 2012 Sep;78(17):6380-5. doi: 10.1128/AEM.00648-12. Epub 2012 Jun 29.
7
Effects of sequential and simultaneous applications of bacteriophages on populations of Pseudomonas aeruginosa in vitro and in wax moth larvae.噬菌体序贯和同时应用对体外和蜡螟幼虫中铜绿假单胞菌种群的影响。
Appl Environ Microbiol. 2012 Aug;78(16):5646-52. doi: 10.1128/AEM.00757-12. Epub 2012 Jun 1.
8
Bacteriophage Delivery by Nebulization and Efficacy Against Phenotypically Diverse Pseudomonas aeruginosa from Cystic Fibrosis Patients.通过雾化递送噬菌体及其对来自囊性纤维化患者的表型多样的铜绿假单胞菌的疗效
J Aerosol Med Pulm Drug Deliv. 2015 Oct;28(5):353-60. doi: 10.1089/jamp.2014.1172. Epub 2015 Feb 25.
9
In vitro and in vivo antibacterial activity of environmental bacteriophages against Pseudomonas aeruginosa strains from cystic fibrosis patients.环境噬菌体对囊性纤维化患者铜绿假单胞菌菌株的体外和体内抗菌活性
Appl Microbiol Biotechnol. 2015 Jul;99(14):6021-33. doi: 10.1007/s00253-015-6492-6. Epub 2015 Mar 12.
10
A genetic approach to the development of new therapeutic phages to fight pseudomonas aeruginosa in wound infections.利用遗传方法开发新的治疗性噬菌体来对抗伤口感染中的铜绿假单胞菌。
Viruses. 2012 Dec 21;5(1):15-53. doi: 10.3390/v5010015.
引用本文的文献
1
Mechanisms and Impact of Biofilms and Targeting of Biofilms Using Bioactive Compounds-A Review.生物膜的机制和影响，以及利用生物活性化合物靶向生物膜——综述。
Medicina (Kaunas). 2021 Aug 18;57(8):839. doi: 10.3390/medicina57080839.
2
Gallium(III)-Salophen as a Dual Inhibitor of Heme Sensing and Iron Acquisition.镓（III）-水杨醛缩邻氨基酚作为血红素感知和铁摄取的双重抑制剂
ACS Infect Dis. 2020 Aug 14;6(8):2073-2085. doi: 10.1021/acsinfecdis.0c00138. Epub 2020 Jul 6.
3
Activity of Cysteamine against the Cystic Fibrosis Pathogen Burkholderia cepacia Complex.半胱胺对囊性纤维化病原体洋葱伯克霍尔德菌复合体的活性。
Antimicrob Agents Chemother. 2016 Sep 23;60(10):6200-6. doi: 10.1128/AAC.01198-16. Print 2016 Oct.
4
Characterization of the Newly Isolated Lytic Bacteriophages KTN6 and KT28 and Their Efficacy against Pseudomonas aeruginosa Biofilm.新分离的裂解性噬菌体KTN6和KT28的特性及其对铜绿假单胞菌生物膜的作用效果
PLoS One. 2015 May 21;10(5):e0127603. doi: 10.1371/journal.pone.0127603. eCollection 2015.
5
Evolution and impact of bacterial drug resistance in the context of cystic fibrosis disease and nosocomial settings.囊性纤维化疾病及医院环境背景下细菌耐药性的演变与影响
Microbiol Insights. 2013 Apr 14;6:29-36. doi: 10.4137/MBI.S10792. eCollection 2013.
6
Clostridium difficile phages: still difficult?艰难梭菌噬菌体：仍然棘手？
Front Microbiol. 2014 Apr 28;5:184. doi: 10.3389/fmicb.2014.00184. eCollection 2014.
7
A novel Pseudomonas aeruginosa bacteriophage, Ab31, a chimera formed from temperate phage PAJU2 and P. putida lytic phage AF: characteristics and mechanism of bacterial resistance.一种新型铜绿假单胞菌噬菌体Ab31，一种由温和噬菌体PAJU2和恶臭假单胞菌裂解性噬菌体AF形成的嵌合体：特性及细菌抗性机制
PLoS One. 2014 Apr 3;9(4):e93777. doi: 10.1371/journal.pone.0093777. eCollection 2014.
8
Applying insights from biofilm biology to drug development - can a new approach be developed?将生物膜生物学的见解应用于药物开发——能否开发出新方法？
Nat Rev Drug Discov. 2013 Oct;12(10):791-808. doi: 10.1038/nrd4000.
9
The susceptibility of Pseudomonas aeruginosa strains from cystic fibrosis patients to bacteriophages.囊性纤维化患者的铜绿假单胞菌菌株对噬菌体的敏感性。
PLoS One. 2013 Apr 24;8(4):e60575. doi: 10.1371/journal.pone.0060575. Print 2013.
本文引用的文献
1
Bacteriophages φMR299-2 and φNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells.噬菌体 φMR299-2 和 φNH-4 可以消除肺部的铜绿假单胞菌和囊性纤维化肺气道细胞中的铜绿假单胞菌。
mBio. 2012 Mar 6;3(2):e00029-12. doi: 10.1128/mBio.00029-12. Print 2012.
2
Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention.肺部噬菌体疗法治疗铜绿假单胞菌囊性纤维化菌株：迈向治疗和预防的第一步。
PLoS One. 2011 Feb 15;6(2):e16963. doi: 10.1371/journal.pone.0016963.
3
Wide host range and strong lytic activity of Staphylococcus aureus lytic phage Stau2.金黄色葡萄球菌溶菌噬菌体 Stau2 的宿主范围广和裂解活性强。
Appl Environ Microbiol. 2011 Feb;77(3):756-61. doi: 10.1128/AEM.01848-10. Epub 2010 Dec 10.
4
Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections.噬菌体可治疗和预防铜绿假单胞菌肺部感染。
J Infect Dis. 2010 Apr 1;201(7):1096-104. doi: 10.1086/651135.
5
Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection.噬菌体疗法在洋葱伯克霍尔德菌肺部感染模型中的疗效。
J Infect Dis. 2010 Jan 15;201(2):264-71. doi: 10.1086/649227.
6
Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system.噬菌体鸡尾酒预防体外模型系统中绿脓假单胞菌在导管上形成生物膜。
Antimicrob Agents Chemother. 2010 Jan;54(1):397-404. doi: 10.1128/AAC.00669-09. Epub 2009 Oct 12.
7
Bacteriophage-derived enzyme that depolymerizes the alginic acid capsule associated with cystic fibrosis isolates of Pseudomonas aeruginosa.来源于噬菌体的酶，可使与铜绿假单胞菌囊性纤维化分离株相关的藻酸胶囊解聚。
J Appl Microbiol. 2010 Feb;108(2):695-702. doi: 10.1111/j.1365-2672.2009.04469.x. Epub 2009 Jul 13.
8
A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy.一种治疗性噬菌体制剂用于耐抗生素铜绿假单胞菌所致慢性中耳炎的对照临床试验；疗效初步报告
Clin Otolaryngol. 2009 Aug;34(4):349-57. doi: 10.1111/j.1749-4486.2009.01973.x.
9
Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials.用于人体临床试验的经过质量控制的特定噬菌体混合物的小规模生产。
PLoS One. 2009;4(3):e4944. doi: 10.1371/journal.pone.0004944. Epub 2009 Mar 20.
10
The structures of bacteriophages K1E and K1-5 explain processive degradation of polysaccharide capsules and evolution of new host specificities.噬菌体K1E和K1-5的结构解释了多糖荚膜的持续性降解以及新宿主特异性的进化。
J Mol Biol. 2007 Aug 17;371(3):836-49. doi: 10.1016/j.jmb.2007.05.083. Epub 2007 Jun 2.
Zotero 插件